Popular terms

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications.



Date/App# patent app List of recent Cytokine-related patents
01/28/16
20160024504 
 Treating th2-mediated diseases by inhibition of bromodomains patent thumbnailTreating th2-mediated diseases by inhibition of bromodomains
The invention provides methods for treating th2 cytokine-mediated diseases by inhibiting bromodomain function.. .
Genentech, Inc.


01/28/16
20160024472 
 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines patent thumbnailGeneration of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only gm-csf without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as il-4 or il-13, to prevent differentiation into a non-dendritic cell lineage.
Northwest Biotherapeutics, Inc.


01/28/16
20160022772 
 Cytokine receptors as targets for hypertension therapy and methods of use patent thumbnailCytokine receptors as targets for hypertension therapy and methods of use
The present disclosure provides methods of treating or ameliorating hypertension in a subject comprising administering a therapeutically effective amount of an il-1 receptor antagonist.. .
Duke University


01/28/16
20160022748 
 Recombinant vsv for the treatment of tumor cells patent thumbnailRecombinant vsv for the treatment of tumor cells
The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides vsv vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said vsv vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type vsv vector.
University Of Miami


01/28/16
20160022616 
 Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells patent thumbnailMethod for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors.

01/21/16
20160018401 
 Methods of prognosis patent thumbnailMethods of prognosis
The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (mic-1) in a test body sample such as serum..
St Vincent's Hospital Sydney Limited


01/21/16
20160017277 
 Cell culture media composition and methods of producing thereof patent thumbnailCell culture media composition and methods of producing thereof
A serum free cell culture media, wherein the media is adapted to be conditioned by culturing a first set of eukaryotic cells in the media, wherein the first set of eukaryotic cells use an expression vector to excrete levels of desired complex proteins into the media; wherein said desired complex proteins include human growth hormone (hgh), growth hormone-like growth factors, insulin-like growth factors, insulin, modified insulins, cytokines, mitogenic proteases and mixtures thereof; and wherein the media is adapted to grow a set of eukaryotic cells.. .
Neuclone Biologics Pty Ltd


01/21/16
20160015785 
 Modulating ischemic injury patent thumbnailModulating ischemic injury
The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


01/21/16
20160015749 
 Engager cells for immunotherapy patent thumbnailEngager cells for immunotherapy
Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule.
Celgene Corporation


01/14/16
20160011192 
 Method and kit for cytokine analysis from a human whole blood sample patent thumbnailMethod and kit for cytokine analysis from a human whole blood sample
The invention further relates to an associated diagnostic kit and to the use thereof. The invention is applied in medical diagnostics and medical research..

01/14/16
20160010061 

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1


Methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes.
Eastern Virginia Medical School


01/14/16
20160008438 

Composition for preventing or treating sepsis


Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of tnf, il-1, and il-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.
Kael-gemvax Co., Ltd.


01/07/16
20160003804 

Compositions and methods for modulating c-rel-dependent cytokine production


The present invention is directed to compositions and methods for modulating c-rel-dependent cytokine production without materially altering the level of expression of nfκb and/or the amount of iκb. The present invention is also directed to screening for modulators of c-rel activity as determined by assaying for altered subcellular localization of c-rel but where the level of expression of nfκb and/or the amount of iκb is materially unaltered..
Synta Pharmaceuticals Corporation


01/07/16
20160002340 

Zcytor17 heterodimeric cytokine receptor monoclonal antibodies


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000874 

Modulating ischemic injury


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


01/07/16
20160000867 

Compositions and methods for modulating the immune system


A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc


01/07/16
20160000842 

Oncolytic virus


Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as cd3, for example, on t cells and an antigen recognition domain that recognizes a tumor antigen, such as epha2, her2, gd2, or glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.
Baylor College Of Medicine


12/31/15
20150376707 

Methods of diagnosing and treating inflammatory bowel disease


The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease.
Cedars-sinai Medical Center


12/31/15
20150374974 

Methods and multi-vessel renal neuromodulation


Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


12/31/15
20150374848 

Methods for the treatment of head and neck squamous cell carcinoma


This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (cdmab), optionally in combination with one or more cdmab, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or cdmab of the instant invention.
University Of Miami


12/31/15
20150374656 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

12/24/15
20150368362 

Anti-histone therapy for vascular necrosis in severe glomerulonephritis


Severe glomerulonephritis involves cell necrosis as well as netosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (nets). Histones released by neutrophils undergoing netosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells.
Immunomedics, Inc.


12/17/15
20150361167 

Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)


Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate mcp-1 (mcp-1 n1pe).. .
Probiodrug Ag


12/17/15
20150359785 

Treatment of inflammation using alpha 7 receptor-binding agonists


Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor.
The Feinstein Institute For Medical Research


12/17/15
20150359240 

Cytokine, chemokine and growth factors in donor human milk


Donor milk has become a standard of care for feeding preterm infants, particularly those with gestational ages of 34 weeks or less, whose mothers are not lactating or not producing sufficient milk quantities. However, prior to distribution, donor milk is required to undergo pasteurization, typically using the holder method, which is believed to destroy immune proteins in the milk and denature many other proteins.
University Of South Florida


12/10/15
20150352218 

Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom


1h-imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed..
3m Innovative Properties Company


12/03/15
20150344934 

Novel high throughput assay for finding new jak3 interacting compounds, biomolecules, and inhibitors.


Janus kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of jak3 was associated with human hematologic and epithelial malignancies.

12/03/15
20150343055 

Compositions and methods using recombinant mhc molecules for the treatment of stroke


Two-domain mhc polypeptides are useful for modulating activities of antigen-specific t-cells, including for modulating pathogenic potential and effects of antigen-specific t-cells. Exemplary mhc class ii-based recombinant t-cell ligands (rtls) of the invention include covalently linked β1 and α1 domains, and mhc class i-based molecules that comprise covalently linked α1 and α2 domains.
The United States Government As Represented By The Department Of Veterans Affairs


12/03/15
20150342918 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids in a mammalian subject.
Biosuccess Biotech Co. Ltd.


11/26/15
20150338394 

Induction of a parasitemia and preventing neuroinflammation by binding cholinergic receptors in apicomplexan infections using levamisole hcl


Equine protozoal myeloencephalitis (epm) is the most commonly diagnosed infectious neuro-degenerative in horses. Important advances have been made in the biology of s.

11/26/15
20150337010 

Method for treating or preventing liver related diseases


This invention discloses an isolated peptide containing an amino acid sequence of seq id no.1. The isolated peptide is capable of providing the effects in suppressing hepatocyte apoptosis, attenuating hepatic triglyceride accumulation, suppressing the expression of inflammatory cytokines, inhibiting expression of pro-apoptotic proteins, enhancing expression of survival factor and inhibiting the expression of biomarker of hepatic fibrosis.
Tunghai University


11/26/15
20150335719 

Intravitreal injection of a chimeric phage endolysin ply187; protection from staphylococcus aureus endophthalmitis


The treatment of endophthalmitis is challenging due to the emergence of mdr bacteria. We evaluated the therapeutic potential of ply187an-ksh3b, a chimeric phage endolysin derived from the ply187 prophage in a mouse model of staphylococcus aureus endophthalmitis.
Wayne State University


11/12/15
20150323546 

Biomarkers in inflammatory bowel disease


The present invention provides a method of determining whether a patient with inflammatory bowel disease (ibd) and who has been treated with anti tnfα therapy is in immunological remission (ir), said method comprising determining the level of a cytokine selected from tnfα, il-17 and ifn-γ in a g1 mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in ir and continuing treatment if said patient is not in ir..
University Of TromsØ


11/05/15
20150314127 

Methods for catheter-based renal neuromodulation


Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


11/05/15
20150313946 

Methods modulating immunoregulatory effect of stem cells


The present invention provides methods or kits with inflammatory cytokines to pretreat 1-iscs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, parkinson's disease, chronic infections, and gvhd. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (jvfscs)..
Rutgers, The State University Of New Jersey


10/29/15
20150307624 

Use of adcc-optimized antibodies for treating weak patients


The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high adcc activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting cd16 fcgr3a-158f homozygote or fcgr3a-158v/f heterozygote polymorphism.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies


10/29/15
20150307577 

Chemokine-cytokine fusion proteins and their applications


The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a tnf-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.. .

10/29/15
20150306142 

Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes


It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory t cells. It is also described an in vitro method for obtaining a genetically modified memory t cell population.
Ospedale San Raffaele S.r.l.


10/29/15
20150305357 

Apparatus and methods for pasteurization of human milk


The present invention relates to a method and apparatus for the inactivation of a biological contaminant in a human milk product by exposing the milk product to uv by imparting a vortical flow to the milk product. The exposure inactivates or reduces the amount of a contaminant in the milk product; and the activity of a bioactive component present in the milk product is not substantially reduced.
Carag Ag


10/22/15
20150301062 

Method for diagnosing and treating fibromyalgia


The invention provides methods, kits and reagents for diagnosing fibromyalgia (fm) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of fm in the individual..
Epicgenetics, Llc


10/22/15
20150301017 

Methods of diagnosing proliferative disorders


The present invention relates to methods of diagnosing and/or prognosing proliferative disorders, especially brain cancers (e.g. Gliomas).
University Of Central Lancashire


10/22/15
20150299777 

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


10/22/15
20150299710 

Inhibitory oligonucleotide and use thereof


The inhibitory oligonucleotides (odns) which strongly block nf-κb activation induced by tlr9 agonists and tlr7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-odns.
Sbi Biotech Co., Ltd.


10/22/15
20150299656 

Methods of producing t memory stem cell populations


Provided are methods of producing an isolated t memory stem cell population, the method comprising a) isolating naïve t cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve t cells and expanding the numbers of naïve t cells in the presence of one or more non-specific t cell stimuli, one or more cytokines, and a gsk-3beta inhibitor. Also provided are methods of producing an isolated t memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) cd95+, cd45ro−, and ccr7+; and ii) cd62l+ or one or more of cd27+, cd28+, cd45ra+, and cd127+ to produce an isolated t memory stem cell population.
The United States Of America, As Represented By Th Secretary, Department Of Health And Human Service


10/22/15
20150299325 

Anti-blood dendritic cell antigen 2 antibodies and uses thereof


Antibodies and antibody fragments that bind to bdca2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions..
Biogen Ma Inc.


10/22/15
20150297676 

Composition comprising grim-19 as active ingredient for preventing or treating obesity or lipid-related metabolic diseases


The present invention relates to a composition comprising grim-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises grim-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors.
Catholic University Industry Academic Cooperation Foundation


10/22/15
20150297616 

A inhibiting the expression of il-22 in activated t-cells


The present invention relates to a method of inhibiting the upregulation of the expression of the proinflammatory cytokine interleukin-22 (il-22) in activated and differentiated human t-cells, said upregulation being induced by administration of a therapeutically effective amount of a phosphodiesterase 4 (pde4) inhibitor. The method comprises administering, either sequentially to or simultaneously with the administration of the pde4 inhibitor, a vitamin d receptor agonist in an amount 3) sufficient to inhibit the upregulation of il-22 expression..
Leo Pharma A/s


10/22/15
20150297536 

Curcumin compositions and uses thereof


Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability.
Omniactive Health Technologies Limited


10/15/15
20150290219 

Composition comprising gpcr19 agonist as an active ingredient for preventing or treating allergic dermatitis


The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a g protein-coupled receptor19 (gpcr19) agonist, specifically sodium taurodeoxycholate (hy2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases.

10/15/15
20150290148 

Method of reducing brain cell damage, inflammation or death


A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (tbi) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a tbi, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition.

10/08/15
20150284686 

Method for culturing mesenchymal stem cells


Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mm and magnesium in a concentration of from 1.0 to 3.0 mm under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability.

10/08/15
20150284444 

Pharmaceutical composition for cancer treatment including fusion protein


An object of the present invention is to use fusion proteins of cancer-specific antigens and cytokines as a preventive or therapeutic agent for cancer. The present invention provides a pharmaceutical composition for the prevention or treatment of a cancer, comprising as active ingredients fusion proteins each comprising a cancer-specific antigen with a cytokine selected from the group consisting of human il2 (hil2), human il4 (hil4), human il7 (hil7), human gmcsf (hgmcsf), mouse il4 (mil4), and mouse gmcsf (mgmcsf)..

10/08/15
20150283233 

Compositions and methods for enhancing immune responses


Compositions and methods for inducing, enhancing, or promoting an immune response are disclosed. In some embodiments the increased immune response is against an antigen such as a tumor antigen or a viral antigen.

10/08/15
20150283176 

Pharmaceutical composition for preventing or treating cancers comprising dendritic cells with dab2 gene silenced


Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down dab2 gene. The composition includes a dendritic cell in which a dab2 gene is knocked down or knocked out or activity of a dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic t cell lymphocyte (ctl) and related t cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer..

10/08/15
20150283127 

Saquinavir-no for immunomodulation


The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

10/01/15
20150276759 

Method and determining a mammal's exposure to chemical or biological agents


Cellular immunologic methods are disclosed for determining human health effects of exposures to environmental molds and toxins. In one embodiment, a method for assessing a patient's exposure to a mold strain is provided.
Epicgenetics Llc


10/01/15
20150276716 

Method for evaluating effect of cytokine on metabolic activity of cytochrome p450, and drug screening method


Provided is a technique that uses an established hepatocyte cell line in a method for evaluating an effect of a cytokine on a metabolic activity of a cytochrome p450 and in a method for evaluating a drug which interacts with a cytokine. The method for evaluating an effect of a cytokine on a metabolic activity of a cytochrome p450 includes: culturing an established hepatocyte cell line by using a culture chamber (10) including culture rooms (11), to thereby form spheroids (9); and evaluating the presence or absence of induction or attenuation of the cytochrome p450 after bringing a spheroid-shaped established hepatocyte cell line into contact with a test solution containing the cytokine in the culture chamber for one hour or more and less than 96 hours..
Kuraray Co., Ltd.


10/01/15
20150273129 

Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome


Provided is a therapeutic device that includes tubing; at least one pump; and a column or filter capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome. Methods for treating and/or preventing post-resuscitation syndrome that include the use of such a device, or a filter or column capable of selectively removing inflammatory biomarkers, are also provided..
Zoll Medical Corporation


10/01/15
20150272171 

Method for the detoxification of gluetn proteins from grains of cereal


With the use of the method gluten proteins undergo structural changes that do not activate in patients suffering from celiac disease, the cascade of inflammatory cytokines. Such structural changes, in addition, do not affect the technical properties of the flours that form the dough, therefore allowing the preparation of detoxified products, similar in taste and appearance to those commonly used in mediterranean diet and which are intended not only for the people who suffer from intolerance to gluten, but for the whole population.

09/24/15
20150266901 

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines


Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company


09/24/15
20150265705 

Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof


The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-pd-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer..
E. R. Squibb & Sons, L.l.c.


09/24/15
20150265685 

Apyrase therapy for fibroproliferative disorders, pulmonary hypertension, and heart failure


This invention provides new methods of treating subjects with fibroproliferative disease such as pulmonary hypertension (e.g. Pulmonary arterial hypertensions), posthrombotic syndrome associated with venous thrombosis, or ventricular heart failure associated with fibroproliferative disease.
Apt Therapeutics, Inc.


09/17/15
20150258143 

Method of providing cellular therapy using modified natural killer cells or t lymphocytes


A method of decreasing cytokine production and release is disclosed. In one embodiment, the method comprises the step of providing cytotoxic cells to a subject wherein the cells are preferably natural killer cells or t lymphocytes and are genetically modified to express a chimeric antigen receptor comprising a first element that is an extracellular antigen receptor and a second intracellular element that is a signaling moiety comprising altered adap-dependent or fyn-dependent signaling such that downstream signaling causing cytokine release is decreased.
Bloodcenter Research Foundation


09/17/15
20150257998 

Novel trpv1 inhibitory peptides and composition for skin-aging protection or wrinkle improvement comprising the same


The present invention relates to a novel trpv1 inhibitory peptide and a composition for skin-aging prevention and wrinkle improvement comprising the same as an active ingredient. The trpv1 inhibitory peptide of the present invention inhibits the expressions of mmp and proinflammatory cytokines induced by uv exposure and reduces skinfold thickness and intracellular ca2+ so that it can be effectively used as an active ingredient of the composition for skin-aging prevention, wrinkle improvement, skin-whitening, or alleviating inflammation, irritation, or pain..
Snu R&db Foundation


09/10/15
20150250827 

Bio-mimetic ultrathin hydrogel coatings for pancreatic islet transplantation


The present disclosure provides multifunctional cytoprotective materials applied to coat living cells or aggregates of cells such as, but not limited to, pancreatic islets. The coating utilizes hydrogen-bonded interactions of a natural polyphenol (tannic acid) with poly(n-vinylpyrrolidone) deposited on the cell aggregate surface via non-ionic layer-by-layer assembly.
The Uab Research Foundation


09/10/15
20150250809 

Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders


The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have tlr4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


09/03/15
20150247848 

Material and methods for diagnosing and treating kawasaki disease and kls


Two patients diagnosed with kls were treated. One patient had severe kls that progressed to the equivalent of pediatric kawasaki disease shock e syndrome (kdss).
Indiana University Research & Technology Corporation




Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.991

4522

1 - 1 - 102